Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

NCT03471260 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Hematopoietic and Lymphoid System Neoplasm
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
DRUG: Ivosidenib
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center